Back to top
more

United Therapeutics Corporation (UTHR)

(Real Time Quote from BATS)

$198.31 USD

198.31
77,804

+0.44 (0.22%)

Updated May 17, 2021 12:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Lags Q1 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

United Therapeutics (UTHR) Misses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

United Therapeutics (UTHR) Down 6.9% Since Last Earnings Report: Can It Rebound?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Q2 Earnings Meet Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 0.00% and 6.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Should You Buy?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Why Is United Therapeutics (UTHR) Up 5% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics